Frank Pallone actually said...

There clearly needs to be some balance between the exclusivity and the cost savings.

I believe that there are many factors to encouraging and ensuring robust investment in medicines.

As Members of Congress, we typically speak about treating disease in sound bites.

Cures and cutting-edge medicines are of no value if their high costs put them out of reach of the patients who need them.